Immune response evaluation in the guinea pigs after immunization with the experimental Puumala virus vaccine
- 作者: Kurashova S.S.1, Balovneva M.V.1, Ishmukhametov A.A.1,2, Teodorovich R.D.1, Popova Y.V.1, Tkachenko E.A.1, Dzagurova T.K.1
-
隶属关系:
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences
- Sechenov First Moscow State Medical University (Sechenov University)
- 期: 卷 12, 编号 5 (2022)
- 页面: 971-975
- 栏目: SHORT COMMUNICATIONS
- URL: https://bakhtiniada.ru/2220-7619/article/view/119179
- DOI: https://doi.org/10.15789/2220-7619-IRE-1956
- ID: 119179
如何引用文章
全文:
详细
In the Russian Federation, the vaccine against hemorrhagic fever with renal syndrome is at the stage of preclinical and clinical trials. The aim of the study was to analyze an effect of vaccine schedule on neutralizing antibodies (nAB) dynamics in guinea pig models applied with experimental Puumala virus based hantavirus vaccine (HV). Quantitative evaluation of neutralizing antibodies was presented as antibody titer geometric mean expressed in binary logarithms (log2) by the 50% reduction of focus-forming units (FRNT50) in Vero cell in the focus reduction neutralization test. The HV dual inoculation to guinea pigs was carried out in 14 day intervals, booster injection was applied on day 182 after the onset, in the thigh muscle tissue by using 0.3 ml undiluted (HV-u/d) and in the 1/10 dilution (HV-1/10). nAB titer on day 14 after the first HV-u/d and HV-1/10 injection was measured to be at titer of 5.5±0.3 and 4.8±0.3, respectively. After the second injection, the nAB peak was as high as 9±0.2 on day 42 after the first HV-u/f injection, and 6.5±0.2 on day 14 after the HV-1/10 injection. nAB decreased down to 6.2±0.3 and 5±0.3, respectively, on day 364 after the first injection. The booster HV-u/d and HV-1/10 injection induced increase in nAB up to 9.5±0.3 and 6.5±0.3, respectively. After the booster injection, it induced significantly higher nAB observed on day 238 after the first HV-u/d injection and delayed up to the 294 day for the HV-1/10. The results of the study indicated the early formation of the immune response, long-term nAB persistence and significantly enhanced immune response after the booster injection on day 182, which indicated a potential for the booster injection a year later. The immunological efficacy and protective activity of the vaccine schedule may be finally assessed according to the results of clinical trials.
作者简介
S. Kurashova
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences
编辑信件的主要联系方式.
Email: svetlanak886@yandex.ru
PhD (Medicine), Leading Researcher, Laboratory of Hemorrhagic Fevers
俄罗斯联邦, MoscowM. Balovneva
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences
Email: mashasm@yandex.ru
PhD (Biology), Leading Researcher, Laboratory of Hemorrhagic Fevers
俄罗斯联邦, MoscowA. Ishmukhametov
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences; Sechenov First Moscow State Medical University (Sechenov University)
Email: ishmukhametov@chumakovs.su
RAS Full Member, PhD, MD (Medicine), Professor, General Director, Head of the Department of Organization and Research of Immunobiological Technologies
俄罗斯联邦, Moscow; MoscowR. Teodorovich
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences
Email: rostislavteo@mail.ru
Researcher, Laboratory of Hemorrhagic Fevers
俄罗斯联邦, МоскваYu. Popova
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences
Email: popova_jv@chumakovs.su
Researcher, Laboratory of Hemorrhagic Fevers
俄罗斯联邦, MoscowE. Tkachenko
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences
Email: evgeniytkach@mail.ru
PhD, MD (Medicine), Professor, Scientific Supervisor
俄罗斯联邦, MoscowT. Dzagurova
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences
Email: dzaguron@gmail.com
PhD, MD (Medicine), Head of the Laboratory of Hemorrhagic Fevers
俄罗斯联邦, Moscow参考
- Бархалева О.А., Воробьева М.С., Ладыженская И.П., Ткаченко Е.А., Дзагурова Т.К. Вакцина против геморрагической лихорадки с почечным синдромом // БИОпрепараты. Профилактика, диагностика, лечение. 2011. Т. 41, № 1. С. 27–30. [Barkhaleva О.А., Vorobyeva М.S., Ladizhenskaya I.P., Tkachenko E.A., Dzagurova T.K. Vaccine against hemorrhagic fever with kidney syndrome. BIOpreparaty. Profilaktika, diagnostika, lechenie = Biopreparations, 2011, vol. 1, pp. 27–30. (In Russ.)]
- Рыбакова А.В., Макарова М.Н. Использование морских свинок в биомедицинских исследованиях // Международный вестник ветеринарии. 2018. № 1. С. 132–137. [Rybakova A.V., Makarova M.N. The use of guinea pigs in biomedical research. Mezhdunarodnyi vestnik veterinarii = International Veterinary Bulletin, 2018, vol. 1, pp. 132–137 (In Russ.)]
- Dzagurova T.K., Klempa B., Tkachenko E.A., Slyusareva G.P., Morozov V.G., Auste B., Kruger D.H. Molecular diagnostics of hemorrhagic fever with renal syndrome during a Dobrava virus infection outbreak in the European part of Russia. J. Clin. Microbiol., 2009, vol. 47, no. 12, pp. 4029–4036. doi: 10.1128/JCM.01225-09
- Egorova M.S., Kurashova S.S., Ishmukhametov A.A., Balovneva M.V., Devyatkin A.A., Safonova M.V., Ozherelkov S.V., Khapchaev Yu.Kh., Balkina A.S., Belyakova A.V., Dzagurova T.K., Tkachenko E.A. Real-time PCR assay development for the control of vaccine against hemorrhagic fever with renal syndrome. Probl. Viral., 2021, vol. 66, no. 1, pp. 65–73. doi: 10.36233/0507-4088-30
- Ghimire T.R. The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. Springerplus, 2015, vol. 4, no. 1, pp. 1–18.
- Goldblatt D., Southern J., Andrews N. J., Burbidge P., Partington J., Roalfe L., Pinto V.M., Thalasselis V., Plestedd E., Richardson H., Snape M.D., Miller E. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1+1) compared with two primary doses and a booster (2+1) in UK infants: a multicentre, parallel group randomised controlled trial. Lancet Infect. Dis., 2018, vol. 18, no. 2, pp. 171–179. doi: 10.1016/S1473-3099(17)30654-0
- Kurashova S.S., Ishmukhametov A.A., Dzagurova T.K., Egorova M.S., Balovneva M.V., Nikitin N.A., Evtushenko E.A., Karpova O.V., Markina A.A., Aparin P.G., Tkachenko P.E., Lvov V.L., Tkachenko E.A. Various adjuvants effect on immunogenicity of Puumala virus vaccine. Front. Cell. Infect. Microbiol., 2020, vol. 10: 545371. doi: 10.3389/fcimb.2020.545371
- Meites E., Szilagyi P.G., Chesson H.W., Unger E.R., Romero J.R., Markowitz L.E. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. Am. J. Transplant., 2019, vol. 19, no. 11, pp. 3202–3206. doi: 10.1111/ajt.15633
- Mittal M.K. Revised 4-dose vaccine schedule as part of postexposure prophylaxis to prevent human rabies. Pediatr. Emerg. Care, 2013, vol. 29, no. 10, pp. 1119–1121. doi: 10.1097/PEC.0b013e3182a63125
- Tkachenko E.A., Ishmukhametov A.A., Dzagurova T.K., Bernshtein A.D., Morozov V.G., Siniugina A.A., Kurashova S.S., Balkina A.S., Tkachenko P.E., Kruger D.H., Klempa B. Hemorrhagic fever with renal syndrome Russia. Emerg. Infect. Dis., 2019, vol. 25, no. 12, pp. 2325–2328. doi: 10.3201/eid2512.181649
- Vaheri A., Strandin T., Hepojoki J., Sironen T., Henttonen H., Mäkelä S., Mustonen J. Uncovering the mysteries of hantavirus infections. Nat. Rev. Microbiol., 2013, vol. 11, no. 8, pp. 539–550.
补充文件
